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Contribution 
What are the novel findings of this work? 
The present study represents the most and comprehensive review of the outcomes of TTTS according 
to Quintero staging system. The overall survival in MCDA pregnancies complicated by TTTS is 
higher at earlier Quintero stages (I-II) than stage III and IV. Neurological morbidity occurred in about 
10% of all cases and was higher in stage II, III and IV. 
 
 What are the clinical implications of this work? 
Further RCTs are needed to elucidate the optimal management of stage I TTTS. 
Laser therapy is currently the best available approach for stage II-IV TTTS as perinatal survival rates 
are still satisfying even at stage III and IV, particularly when considering at least one survivor
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ABSTRACT  
Objectives: To report the outcomes of twin-twin transfusion syndrome (TTTS) according to 
Quintero staging system. 
Methods:  Medline, Embase and Cinahl databases were searched for studies reporting outcomes of 
TTTS stratified by Quintero staging (I-V). The primary outcome was the survival rate according to 
TTTS stage. The secondary outcomes were gestational age at birth (weeks), preterm birth (PTB) <34, 
32 and 28 weeks of gestation and neonatal morbidity. Outcomes were reported according to different 
management options (expectant, laser therapy or amnioreduction) for stage I, including only cases 
treated with laser therapy for stages II-IV and only those managed expectantly for stage V.  Random-
effect head-to-head meta-analyses were used to analyze the extracted data. 
Results: Twenty-six studies (2699 twin pregnancies) were included. 610 (22.6%) were diagnosed at 
Quintero stage I, 692 (25.6%) at stage II, 1146 (42.5%) at stage III, 247 (9.2%) at stage IV and 4 
(0.1%) at stage V. Survival of at least one twin occurred in 86.9% (95% CI 84.0-89.7; 456 cases) of 
pregnancies at stage I, 85% (95% CI 79.1-90.1; 514 cases) at stage II, 80.6% (95% CI 75.7-85.1; 865 
cases) at stage III, 82.8% (95% CI 73.6-90.4; 172 cases) at stage IV and 54.6% (95% CI 24.8-82.6; 
5 cases) at stage V. The rate of pregnancies with no survivor was 11.8% (95% CI 8.4-15.8; 69 cases) 
at stage I, 15% (95% CI 9.9-20.9; 76 cases) at stage II, 18.6% (95% CI 14.2-23.4; 165 cases) at stage 
III, 17.2% (95% CI 9.6-26.4; 33 cases) at stage IV and 45.4% (95% CI 17.4-75.2; 4 cases) at stage 
V.  Gestational age at birth was similar in stage I-III TTTS, and gradually decreases in stage IV and 
V. Overall, the incidence of PTB and neonatal morbidity increases as the severity of TTTS increases, 
but data on these two outcomes were limited by the small sample size of the included studies. When 
stratifying the analysis of stage I TTTS according to the type of intervention, perinatal survival of at 
least one twin was 84.9% (95% CI 70.4-95.1; 94 cases) in cases managed expectantly, 86.7% (95% 
CI 82.6-90.4; 249 cases) in those undergoing laser therapy and 92.2% (85% CI 84.2-97.6; 56 cases) 
in those after amnioreduction, while double survival was 67.9% (95% CI 57.0-77.9; 73 cases), 69.7% 
(95% CI 61.6-77.1; 203 cases) and 80.8% (95% CI 62.0-94.2; 49 cases) in the three groups, 
respectively. 
Conclusion: The overall survival in MCDA pregnancies affected by TTTS is higher at earlier 
Quintero stages (I-II), but perinatal survival rates are reasonable even at stage III and IV when treated 
with laser therapy. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases 
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in stage IV and V treated with laser. In pregnancies affected by stage I TTTS, amnioreduction was 
associated with a slightly higher survival compared to laser therapy and expectant management, 
although these findings might only be confirmed by future head-to-head, randomized trials. 
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INTRODUCTION  
Monochorionic (MC) twin pregnancies are at increased risk of perinatal mortality and morbidity 
compared to dichorionic (DC) gestations, mostly due to conditions arising from their peculiar 
placental vascular arrangement, such as twin-twin transfusion syndrome (TTTS), twin anemia-
polycythemia (TAPS) and twin reverse arterial perfusion (TRAP) sequence.1-11  
Although the pathophysiology of TTTS has not been fully elucidated yet, an unbalanced flow through 
the inter-twin vascular anastomoses are critical for the development of TTTS, leading to progressive 
hemodynamic derangements mainly consisting of cardiac overload of the recipient and chronic 
hypoperfusion and hypoxemia in the donor twin.2,12 
TTTS is commonly graded according to the ultrasound  staging system  proposed by Quintero in 1999 
and consisting in five progressive stages characterized by the presence of  oligohydramnios/ 
polyhydramnios sequence (stage I), absent visualization of the donor’s bladder (stage II), Doppler 
anomalies (stage III), fetal hydrops (stage IV) and eventually fetal demise of one or both twins (stage 
V).13 While the majority of stage I TTTS remains stable or regress even without intervention,14-15 
fetoscopic laser ablation of placental anastomoses is the treatment of choice for stages II-IV TTTS.2,16 
Anyway, data on perinatal mortality and morbidity stratified by Quintero staging system in 
monochorionic twin pregnancies affected by TTTS are still scant. 
More recently, another classification system mainly focused upon the echocardiographic features of 
the recipient twin, known as the CHOP (Children’s Hospital of Philadelphia) score, has been 
proposed  to correlate with the Quintero staging system and clinical outcome of MC twins affected 
by TTTS, although its actual prognostic value is still debated.17-18 
In general, the overall survival rates of 50-70% can be expected after fetoscopic laser for the treatment 
of TTTS, with a 30-50% chance of overall perinatal death and 5-20% chance of long-term 
neurological impairment.2 However, these figures referred to the overall population of MC twins 
affected by TTTS, while the occurrence of the different adverse outcome according to the individual 
stage of the disease has not been consistently reported yet. 
The aim of this systematic review was to report the outcome of TTTS according to the Quintero stage 
of the disease. 
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METHODS  
Protocol, information sources and literature search  
This review was performed according to an a-priori designed protocol and recommended for 
systematic reviews and meta-analysis.19-21 Medline and Embase databases were searched 
electronically on October 2019 utilizing combinations of the relevant medical subject heading 
(MeSH) terms, key words, and word variants for “twin-twin transfusion syndrome”, “monochorionic 
pregnancies”, “ultrasound” and “outcome”. The search and selection criteria were restricted to 
English language. Reference lists of relevant articles and reviews were hand searched for additional 
reports. Prisma guidelines were followed.22-24 The study was registered with the PROSPERO 
database (registration number: CRD42020150971).  
  
Outcomes measures, study selection and data collection  
The primary outcome was the survival rate, defined as: 
• No survival: defined as death of both twins before birth 
• Single survivor: defined as the survival to birth of only one twin 
• Double survival: defined as survival to birth of both twins 
• Survival of at least one twin 
 
Secondary outcomes were: 
• Gestational age at birth (expressed in weeks) 
• Respiratory morbidity (including respiratory distress syndrome, transient tachypnoea of the 
new-born, continuous positive airway pressure for at least 24 hours, mechanical ventilation, 
need for supplemental oxygen, pulmonary hypertension or bronchopulmonary dysplasia) 
• Neurological morbidity (including seizures, intra-ventricular haemorrhage and periventricular 
leukomalacia of any grade detected on ultrasound scan) 
• Severe neurological morbidity (including seizures, intra-ventricular haemorrhage grade III 
and IV and periventricular leukomalacia grades II and III detected on ultrasound scan) 
• Composite morbidity, defined as the occurrence of either of the morbidities  
• Preterm birth (PTB) <34 weeks of gestation 
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• Preterm birth (PTB) <32 weeks of gestation 
• Preterm birth (PTB) <28 weeks of gestation 
 
 
All the explored outcomes were reported for monochorionic diamniotic (MCDA) twins according to 
the Quintero staging system of the disease,13 defined as: 
- Stage I: defined as the presence of oligohydramnios (maximum vertical pocket, MVP <2 cm) 
in the donor and polyhydramnios (MVP>8 cm) in the recipient twin.   
- Stage II: defined as the non-visualization of fetal bladder in donor twin over 60 minutes of 
observation. 
- Stage III: defined upon the presence of Doppler abnormalities (absent or reversed umbilical 
artery diastolic flow, reversed ductus venosus a-wave flow, pulsatile umbilical vein flow). 
- Stage IV: defined as the presence of hydrops in one or both twins. 
- Stage V: defined as the occurrence of fetal demise in one or both twins. 
 
We aimed to explore the occurrence of mortality and morbidity in the overall populations of twins 
and in the donor and recipient twin separately.   
For pregnancies affected by stage I, we reported all the explored outcomes according to different 
management options (expectant management, laser therapy and amnioreduction). The reason for this 
choice was based upon the fact that the optimal management for these pregnancies has still to be 
ascertained.14 For stage II-IV TTTS, only studies reporting the outcome of pregnancies treated with 
laser were considered suitable for the inclusion in the current systematic review. Finally, for cases 
affected by stage V, we report the outcome only for those cases managed expectantly. Studies 
including higher order multiple gestations, those including monochorionic monoamniotic (MCMA) 
twin pregnancies, structural or chromosomal anomalies and those from which data the observed 
outcomes stratified by the stage of the disease could not be extrapolated were excluded. Studies 
published before 2000 were also excluded, as we considered that advances in prenatal imaging 
techniques, improvements in the diagnosis and treatment of TTTS make them less relevant. Only full 
text articles were considered eligible for the inclusion; case reports, conference abstracts and case 
series with fewer than 5 cases were excluded in order to avoid publication bias.  
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Two authors (DDM, ADA) reviewed all abstracts independently. Agreement regarding potential 
relevance was reached by consensus. Full text copies of those papers were obtained, and the same 
two reviewers independently extracted relevant data regarding study characteristics and pregnancy 
outcome. Inconsistencies were discussed by the reviewers and consensus reached or by discussion 
with a third author. If more than one study was published for the same cohort with identical endpoints, 
the report containing the most comprehensive information on the population was included to avoid 
overlapping populations.  
 
Quality assessment, risk of bias and statistical analysis 
Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) 
for cohort studies. According to NOS, each study is judged on three broad perspectives: the selection 
of the study groups; the comparability of the groups; and the ascertainment of the outcome of 
interest.25 Assessment of the selection of a study includes the evaluation of the representativeness of 
the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure and the 
demonstration that the outcome of interest was not present at start of study. Assessment of the 
comparability of the study includes the evaluation of the comparability of cohorts on the basis of the 
design or analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of the 
type of the assessment of the outcome of interest, length and adequacy of follow-up. According to 
NOS a study can be awarded a maximum of one star for each numbered item within the Selection 
and Outcome categories. A maximum of two stars can be given for Comparability.   
 
Random-effect meta-analyses of proportions were used to combine data. For the purpose of the 
analysis, the denominator was represented by the number of twins per each group for the computation 
of  survivors and morbidity, while the number of pregnancies for the assessment of PTB and the 
presence of at least one and two survivors. Funnel plots displaying the outcome rate from individual 
studies versus their precision (1/standard error) were carried out with an exploratory aim. Tests for 
funnel plot asymmetry were not used when the total number of publications included for each 
outcome was less than ten. In this case, the power of the tests is too low to distinguish chance from 
real asymmetry.26-27 
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Between-study heterogeneity was explored using the I2 statistic, which represents the percentage of 
between-study variation that is due to heterogeneity rather than chance. A value of 0% indicates no 
observed heterogeneity, whereas I2 values of ≥50% indicate a substantial level of heterogeneity. All 
analyses were performed using StatsDirect Statistical Software (StatsDirect Ltd Cambridge, United 
Kingdom). 
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RESULTS   
Study selection and characteristics  
1455 articles were identified, 60 were assessed with respect to their eligibility for inclusion and 26 
studies28-53 were included in the systematic review (Table 1, Figure 1, Supplementary Table 1). 
These 26 studies included 2699 MCDA twin pregnancies affected by TTTS. Gestational age at 
diagnosis of TTTS was reported only by ten studies.28,30,32-33,38-39,41,46,48,52 Out of the 2699 pregnancies 
affected by TTTS, 610 (22.6%) were diagnosed at Quintero stage I, 692 (25.6%) at stage II, 1146 
(42.5%) at stage III, 247 (9.2%) at stage IV and 4 (0.1%) at stage V. 
Stage I TTTS were treated with laser therapy in 62.4% (285/457 pregnancies), amnioreduction in 
13.1% (60/457 pregnancies) and expectant management in 24.5% (112/457 pregnancies) of cases, 
respectively. 
The majority of stage II-IV TTTS were treated with laser therapy, except for one study30 which 
evaluated the outcome of expectant management even at higher stages of the disease; three 
studies40,41,52 in which TTTS was treated with amnioreduction and/or septostomy; one study50 in 
which both laser therapy and amnioreduction were performed for stage II-IV TTTS. In stage V TTTS, 
one study30 evaluated the outcome of expectant management, while the other one52 does not specify 
whether expectant management or amnioreduction and/or septostomy were performed. 
The results of the quality assessment of the included studies using the NOS scale are presented in 
Table 2. Most of the included studies showed an overall good score regarding the selection and 
comparability of study groups, and for ascertainment of the outcome of interest. The main weaknesses 
of these studies were their retrospective design, small sample size and heterogeneity of outcomes 
observed. Furthermore, studies reporting information of morbidity were affected by the very small 
number of included cases and even smaller number of events, thus making it difficult to extrapolate 
objective evidence on the actual incidence of this outcome in the different stages of the disease. 
 
Synthesis of the results 
Stage I 
Sixteen studies28,29-31,33,35,37-40,42,46,48,51-53 reported information on stage I TTTS.  
There was no survival of either twin in 11.8% of pregnancies affected by stage I TTTS (95% CI 8.4-
15.8; 69/564), while one and two survivors were reported in 17.5% (95% CI 14.4-20.9; 95/560) and 
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70% (95% CI 65.4-74.4; 396/560) of cases, respectively. At least one twin survived in 86.9% of 
pregnancies (95% CI 84-89.7; 456/522) (Table 3; Figure 2).  
Mean gestational age at delivery was 31.1 weeks (95% CI 29.9-32.2) (Table 4; Supplementary Figure 
S1a). PTB <34 and <32 weeks of gestation complicated 50% (95% CI 12.6-98.7; 1/2), and 27.1% 
(95% CI 13.9-42.8; 9/34) of pregnancies complicated by stage I TTTS, respectively, while there was 
no case of PTB <28 weeks of gestation among the included cases (Table 5). 
Three studies reported data on neonatal morbidity.32,46,53 Composite morbidity was reported in 22.9% 
(95% CI 0.1-68.49; 44/188) twins affected by stage I TTTS, neurological and respiratory morbidity 
complicated 1.5% (95% CI 0.02-5.1; 2/148) and 19.1% (95% CI 11.3-29.1; 16/84) of twins after birth 
(Table 6). 
When stratified the analysis according to the different management options - expectant, laser therapy 
or amnioreduction - the mean gestational age at diagnosis was 21.0, 21.4 and 23.5 weeks of gestation, 
respectively (Supplementary Table 2). No twin survived to birth in 15.1% (95% CI 4.9-29.6; 18/112) 
in those cases managed expectantly, in 13.2% (95% CI 9.6-17.4; 36/285) of those having laser 
treatment and in 7.8% (95% CI 2.5-15.8; 4/60) of those undergoing amnioreduction. Survival of at 
least one twin was reported in 84.9% (95% CI 70.4-95.1; 94/112) of cases managed expectantly, 
86.7% (95% CI 82.6-90.4; 249/285) of those having laser therapy and in 92.2% (95% CI 84.2-97.6; 
56/60) of those undergoing amnioreduction. Conversely, it was not possible to perform a 
comprehensive pooled data synthesis on the occurrence of morbidity according to different 




Fourteen studies29,31,34-38,42-44,49,50,51,53 reported information on stage II TTTS.  
There was no survival of either twin in 15.0% (95% CI 9.9-20.9; 76/590) of pregnancies, while one 
and two survivors were reported in 22.4% (95% CI 17.6-27.7; 123/590) and 66.4% (95% CI 52.6-
69.9; 391/590) of cases, respectively. At least one survivor was reported in 85.0% (95% CI 79.1-90.1; 
514/590) of pregnancies affected by TTTS and treated with laser therapy (Table 3; Figure 2). 
Mean gestational age at treatment was 20.3, while mean gestational age at delivery was 31.4 weeks 
(29.5-33.3) (Table 4; Supplementary Table 3; Supplementary Figure S1b). PTB <34, <32 and 28 
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weeks of gestation occurred in 31.3% (95% CI 10.0-58.0; 4/12), 42.8% (95% CI 29.4-56.9; 20/47) 
and  17.6% (95% CI 1.6-45.3; 2/12) of pregnancies, respectively (Table 5). 
Two studies reported data on neonatal morbidity.44,53 Overall, composite morbidity affected 28.8% 
(95% CI 6.8-97.0; 39/124) of twins after birth. Neurological morbidity occurred in 5.2% (95% CI 
0.3-15.4; 6/124), while respiratory morbidity in 70.4% (95% CI 56.4-82-0; 38/54) of twins (Table 6). 
 
Stage III 
Fifteen studies29,31,34-38,42-45,49,50,51,53 reported information on stage III TTTS.  
No survival was observed in 18.6% (95% CI 14.2-23.4; 165/1040) of twin pregnancies affected by 
stage III TTTS and treated with laser, while one and two survivors were reported in 35.0% (95% CI 
29.3-40.8; 341/1040) and 45.4% (95% CI 38.2-52.7; 534/1040) of cases, respectively. At least one 
survivor was reported in 80.6% of pregnancies (95% CI 75.7-85.1; 865/1040) (Table 3; Figure 2).  
Mean gestational age at treatment was 20.2, while mean gestational age at delivery was 31.4 weeks 
(30.0-32.7) (Table 4; Supplementary Table 3; Supplementary Figure S1c), while PTB <34, <32 and 
<28 weeks of gestations complicated 37.3% (95% CI 5.2-78.0; 12/30), 53.3% (95% CI 36.1-70.2; 
32/58) and 9.7% (95% CI 2.0-22.3; 3/30) of cases, respectively (Table 5). 
Two studies reported data on neonatal morbidity.44,53 Composite morbidity affected 29.3% (95% CI 
18.6-91.8; 48/127) twins after stage III TTTS. Finally, neurological and respiratory morbidity were 




Fifteen studies29,31,34-38,42-45,49,50,51,53 reported data on stage IV TTTS.  
There was no survival of either twin in 17.2% of pregnancies (95% CI 9.6-26.4; 33/205), while one 
and two survivors were reported in 27.7% (95% CI 21.9-33.9; 55/205) and 53.7% (95% CI 40.2-66.8; 
117/205) of cases, respectively. At least one survivor was reported in 82.8% of pregnancies (95% CI 
73.6-90.4; 172/205) (Table 3; Figure 2).  
Mean gestational age at treatment was 21.4, while mean gestational age at delivery was 29.9 weeks 
(28.5-31.4) weeks (Table 4; Supplementary Table 3; Supplementary Figure S1d), while PTB <34 and 
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<32 weeks of gestation was reported in 46.5% (95% CI 15.5-79.2; 3/7), 59.9% (95% CI 37.9-80.0; 
11/18), while there was no pregnancy delivered <28 weeks (PP: 0, 95% CI 0-30.7; 0/7) (Table 5). 
Two studies reported data on neonatal morbidity.44,53 Composite neonatal morbidity complicated 
24.1% (95% CI 0.02-71.8; 21/64) of twins after birth, while neurological and respiratory morbidity 
were reported in 5.9% (95% CI 1.6-13.0; 3/64), and 47.6% (95% CI 32.0-63.6; 20/42) of cases, 
respectively (Table 6). 
 
Stage V 
Outcome ascertainment of MC twin pregnancies affected by stage V TTTT was affected by the very 
small number of included cases (9 pregnancies) and even smaller number of events, with only two 
studies30,52 reporting information of the outcomes observed in the present systematic review.  
Death of the co-twin occurred in 45.4% of pregnancies (95% CI 17.4-75.2; 4/9), while the remaining 
twin survived in 54.6% (95% CI 24.8-82.6; 5/9) of cases (Table 3; Figure 2).  
Mean gestational age at delivery was 26.5 (24.4-28.5) weeks (Table 4; supplementary figure S1e), 
while there was no study reporting data on morbidity and on the incidence of PTB at different 
gestational age windows.   
 
Sub-group analyses 
It was not possible to perform a comprehensive pooled data synthesis on the incidence of mortality 
and morbidity in the donor and recipient twin separately and according to the gestational age at 
occurrence of the TTTS due to the very small number of included studies reporting these data. 
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DISCUSSION  
Main findings  
The findings from this systematic review show that the perinatal survival of twin pregnancies 
complicated by TTTS seems to be higher in the first stages (I and II) of the disease, although it 
remains high even in its later phases (stage III and IV). Conversely, the perinatal mortality is higher 
in stage V. Gestational age at birth was similar in stage I-III TTTS, and gradually decreases in stage 
IV and V. Overall, the incidence of PTB and neonatal morbidity increases as the severity of TTTS 
increases, but these data were limited by the small sample size of the included studies.  
When considering the different management options in pregnancies complicated by stage I TTTS 
(expectant management, laser therapy or amnioreduction) the perinatal survival of at least one twin 
was similar, thus making it difficult to extrapolate a robust evidence on the optimal type of 
intervention when stage I TTTS is diagnosed.  
 
Strengths and limitations  
The small number of cases in some of the included studies, their retrospective non-randomized 
design, lack of standardized criteria for the antenatal surveillance, management and timing of delivery 
of MCDA twin pregnancies complicated by TTTS represent the major limitations of this systematic 
review. Furthermore, some of the included studies reported data on the outcomes of stage II-IV TTTS 
treated with different management options - even though fetoscopic laser therapy is currently the gold 
standard for this subset of pregnancies – and it was not always possible to extrapolate information on 
cases treated with laser therapy only. It was not possible to draw any convincing evidence on stage 
V TTTS or on neonatal morbidity due to the negligible number of cases evaluated in this review. 
Another major limitation of the present review was the lack of stratification of the analysis according 
to the cardiovascular status of the affected twins, that previous studies have claimed as a potential 
predictor of the outcome of pregnancies affected by TTTS, irrespective of the Quintero stage. 
Unfortunately, the large majority of these studies did not report information according to TTTS 
different stages, thus making it impossible to integrate such information in the outcome 
ascertainment. Finally, we could not explore the effect of individual Doppler indices in affecting the 
outcome of twins undergoing laser as this information was not provided by the large majority of 
included studies.  
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Interpretation of findings and comparison with other published evidence  
The findings from this study are in line with those reported in 2016 by Khalil et al14 in terms of overall 
survival in Quintero stage I TTTS, but differ from the above-mentioned meta-analysis and a previous 
systematic review by Rossi and D’Addario15 when stratifying outcomes according to the type of 
intervention. When focusing on higher Quintero stages treated with laser therapy, our results in terms 
of perinatal survival are concordant with those reported in the most recent and largest series54-56 that 
showed a double survival rate ranging between 50-65% and that of at least one twin survival of 75-
90% at stage II-IV. Likewise, our findings are also consistent with a recent systematic review 
reporting perinatal outcome of pregnancies affected by TTTS treated with laser therapy over the past 
25 years, in which the double survival rate was 62%, while at least one survivor was reported in up 
to 88% in the subgroup analysis of studies published between 2011 and 2014.57  
Our results showed similar incidence of neonatal neurological morbidity at birth, compared with a 
previous meta-analysis by Rossi et al who reported an incidence of less than 10% and was comparable 
at Quintero stage II-IV, while it was lower at stage I.58 
 
Clinical and research implications  
While laser therapy is considered the gold standard for stage II-IV TTTS,2 the optimal management 
for Quintero stage I TTTS is still a matter of debate, as there are no published randomized controlled 
trials (RCT) exploring different management options. 
The findings from this review showed that, although perinatal survival of at least one twin was almost 
similar among the three management options, amnioreduction was associated with a slightly higher 
survival of both twins and lower chance of double fetal loss. These results should be interpreted with 
caution because the included studies were not designed to compare these strategies and were not 
powered for most of the observed outcomes. Amnioreduction is not exempt of procedure-related 
complications, such as unintended septostomy, preterm premature rupture of membranes, abruption 
or infection,2 and the rate of progression of stage I TTTS was reported to be 30% when 
amnioreduction was the first-line therapy, compared with none in pregnancies treated with laser.15 
Further head-to-head RCTs are needed in order to elucidate the optimal management in pregnancies 
affected by stage I TTTS. 
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Fetoscopic selective laser ablation of anastomotic vessels followed by equatorial dichorionization 
(the Solomon technique) is currently recommended as the best available approach to treat stage II-IV 
TTTS between 16 and 26 weeks of gestation.2 Our review showed that the overall survival was higher 
at earlier Quintero stages (I-II), and the perinatal survival rates were still satisfying even at stage III 
and IV.  
In the present study, respiratory and neurological morbidities were intuitively lower at stage I TTTS 
(any management), while increased at stage II-IV (treated with laser), with respiratory morbidity 
affecting the majority of twins and neurological morbidity impairing up to 9% of newborns. The 
etiology of cerebral morbidity is still uncertain, as neurodevelopmental outcome was shown to be 
similar in monochorionic twins treated with laser therapy and dichorionic control subjects, thus 
leading to the hypothesis that neurological impairment could rather represent a detrimental effect 
which is inherent in prematurity.59 
 
Conclusion 
The overall survival in MCDA pregnancies complicated by TTTS is higher at earlier Quintero stages 
(I-II) than stage III and IV. Gestational age at birth was similar in stage I-III TTTS, and gradually 
decreases in stage IV and V.  
Further RCTs and long-term follow up studies are needed in order to elucidate the optimal 
management of pregnancies affected by stage I TTTS and to quantify the risk of neurological 
disability according to the severity of disease. 
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Figure legends 
Figure 1. Systematic review flowchart 
Figure 2. Stage I-V TTTS survival rate bar chart 
Figure 3. Stage I TTTS survival rate according to different management options bar chart
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Author Year Country Study design Period considered GA at diagnosis* GA at treatment* Outcomes observed Pregnancies (n) 
Washburn28 2018 USA Retrospective 2006-2016 20.8 (3.7) No treatment GA at birth, mortality 30 
Barbosa29 2018 Brazil Prospective 2012-2016 NR 20.7 (2.9) GA at birth, PTB, mortality 24 
Duryea30 2016 USA Retrospective 1997-2013 24 (17-21) No treatment GA at birth, mortality 20 
Chang31 2016 China Retrospective 2005-2014 NR 20.6 (2.7) GA at birth, mortality 100 
Hinch32 2016 Australia Retrospective 2007-2013 20.7 (19-23.1) NR GA at birth, mortality, morbidity 28 
Emery33 2016 USA Retrospective 2005-2014 21.5 (2.7) NR GA at birth, mortality 124 
Eschbach34 2016 The Netherlands Retrospective 2007-2013 NR 19.7 (17.9-22.2) GA at birth, mortality  
Has35 2014 Turkey Retrospective 2006-2013 NR 21 (16-26) GA at birth, mortality 85 
Ruano36 2013 Spain-USA-Brazil Retrospective 2010-2012 NR 20 (15.4-26) Mortality 102 
Swiatkowska-Freund37 2012 Poland Prospective 2005-2010 NR 20 (16-26) Mortality 94 
Chmait38 2011 USA Prospective 2002-2010 20.6 (2.4) NR GA at birth, mortality 682 
Bebbington39 2010 USA Retrospective 2005-2006 20.9 (0.4) No treatment GA at birth, mortality 42 
Fichera40 2010 Italy Retrospective 1999-2006 NR 21.4 (19.3-24.5) Mortality 34 
Korpraphong41 2010 Thailand Retrospective 2000-2009 22.9 (15-32) No treatment Mortality 25 
Meriki42 2010 Australia Retrospective 2003-2008 NR 20 (16-25) Mortality 79 
Morris43 2010 United Kingdom Prospective 2004-2009 NR 20.2 (18-22) GA at birth, mortality 164 
Cincotta44 2009 Australia Prospective 2002-2007 NR 21 (18-28) GA at birth, mortality, morbidity 100 
Ruano45 2009 Brazil Prospective 2006-2008 NR 22 (19-26) GA at birth, mortality 19 
Wagner46 2009 The Netherlands Retrospective 2000-2007 21 21.2 (2.6) GA at birth, mortality 50 
Middeldorp47 2007 Belgium-The Netherlands Prospective 2000-2004 NR 20 (16-26) GA at birth, mortality 100 
O'Donoghue48 2007 United Kingdom Retrospective 2000-2006 21.3 (15.4-31.5) No treatment GA at birth, mortality 46 
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Table 1. General characteristics of the included studies. 
GA, gestational age; NR, not reported; PTB, preterm birth; *: data reported as mean (standard deviations) or median (range). 
Sepulveda49 2007 Chile Prospective 2003-2006 NR 21 (17-25) GA at birth, PTB, mortality 33 
Gray50 2006 Australia Retrospective 1994-2003 NR 20 (19-22) Mortality 58 
Huber51 2006 Germany Prospective 1999-2003 NR 20.7 (15.9-25.3) GA at birth, mortality 200 
Duncombe52 2004 Australia Prospective 1992-2002 22.1 (19.7-25.4) NR GA at birth, mortality 69 
Quintero53 2003 USA Prospective NR NR 21.1 PTB, mortality, morbidity 173 
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Table 2. Quality assessment of the included studies according to Newcastle-Ottawa Scale (NOS) for cohort studies; a study can be awarded a 
maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability. 
Author Year Selection Comparability Outcome 
Washburn28 2018    
Barbosa29 2018    
Duryea30 2016    
Chang31 2016    
Hinch32 2016    
Emery33 2016    
Eschbach34 2016    
Has35 2014    
Ruano36 2013    
Swiatkowska-Freund37 2012    
Chmait38 2011    
Bebbington39 2010    
Fichera40 2010    
Korpraphong41 2010    
Meriki42 2010    
Morris43 2010    
Cincotta44 2009    
Ruano45 2009    
Wagner46 2009    
Middeldorp47 2007    
O'Donoghue48 2007    
Sepulveda49 2007    




























Gray50 2006    
Huber51 2006    
Duncombe52 2004    
Quintero53 2003    





Table 3. Pooled proportions for single and double survival in MCDA twin pregnancies affected by TTTS according to the stage of the disease. (95% 
confidence intervals, CI, between parentheses). 
 
Outcome Studies (n) Fetuses (n/N) Raw proportions (95% CI) I2 (%) Pooled Proportions (95% CI) 
 Stage I 
No survivor 16 69/564 11.3 (8.8-14.1) 36.1 11.8 (8.4-15.8) 
One survivor 15 95/560 16.9 (14.0-20.3) 3.6 17.5 (14.4-20.9) 
At least one survivor 15 456/522 87.4 (84.2-90.1) 0.3 86.9 (84.0-89.7) 
Two survivors 15 396/560 70.7 (66.8-74.5) 18.4 70.0 (65.4-74.4) 
 Stage II 
No survivor 14 76/590 12.9 (10.4-15.8) 65.4 15.0 (9.9-20.9) 
One survivor 14 123/590 20.6 (17.8-24.3) 43.5 22.4 (17.6-27.7) 
At least one survivor 14 514/590 87.1 (84.2-89.6) 65.4 85.0 (79.1-90.1) 
Two survivors 14 391/590 54.1 (50.0-58.1) 74 66.4 (52.6-69.9) 
 Stage III 
No survivor 15 165/1040 15.9 (13.8-18.2) 65.8 18.6 (14.2-23.4) 
One survivor 15 341/1040 32.8 (30.0-35.7) 66.9 35.0 (29.3-40.8) 
At least one survivor 15 865/1040 83.2 (80.8-85.3) 66 80.6 (75.7-85.1) 
Two survivors 15 534/1040 51.4 (48.3-54.4) 78.4 45.4 (38.2-52.7) 
 Stage IV 
No survivor 15 33/205 16.1 (11.7-21.8) 56.3 17.2 (9.6-26.4) 
One survivor 15 55/205 26.9 (21.2-33.9) 0 27.7 (21.9-33.9) 
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At least one survivor 15 172/205 83.9 (78.6-88.3) 56.3 82.8 (73.6-90.4) 
Two survivors 15 117/205 57.1 (50.2-63.7) 70.2 53.7 (40.2-66.8) 
 Stage V 
No survivor 2* 4/9 44.4 (18.0-73.3) 0 45.4 (17.4-75.2) 
One survivor 2* 5/9 55.6 (26.7-81.1) 0 54.6 (24.8-82.6) 
 





Table 4. Mean gestational age at birth in MCDA twin pregnancies affected by TTTS, according to the stage of the disease. Weighted means were 
obtained combining data from individual studies to perform meta-analyses of single-group continuous data. For the sake of completeness, raw means 
were also reported. (CI = Confidence Interval). 
 
Disease stage Studies (n) Fetuses  (Total sample) 
Raw mean  
(95% CI) 
Weighted mean  
(95% CI) I
2 (%) 
Stage I 13 527 30.9 (28.9-32.9) 31.1 (29.9-32.2) 87.4 
Stage II 11 437 31.4 (29.9-32.9) 31.4 (29.5-33.3) 91.7 
Stage III 12 750 31.3 (30.0-32.7) 31.4 (30.0-32.7) 87.2 
Stage IV 12 170 30.1 (28.5-31.8) 29.9 (28.5-31.4) 47.3 
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Table 5. Pooled proportions for morbidity in MCDA twins affected by TTTS according to the stage of the disease. (95% confidence intervals, CI, 
between parentheses). 
 
Outcome Studies (n) Fetuses (n/N) Raw proportions (95% CI) I2 (%) Pooled Proportions (95% CI) 
Stage I 
PTB <34 weeks  1 1/2 50.0 (12.6-98.7) - - 
PTB <32 weeks 2 9/34 26.5 (12.9-44.4) 0 27.1 (13.9-42.8) 
PTB <28 weeks 1 0/2 0.0 (0-84.2) - - 
Stage II 
PTB <34 weeks  2 4/12 33.3 (9.9-65.1) 72.3 31.3 (10.0-58.0) 
PTB <32 weeks 3 20/47 42.6 (28.3-57.8) 0 42.8 (29.4-56.9) 
PTB <28 weeks 2 2/12 16.7 (2.1-48.4) 17.7 17.6 (1.6-45.3) 
Stage III 
PTB <34 weeks  2 12/30 40.0 (22.7-59.4) 82.6 37.3 (5.2-78.0) 
PTB <32 weeks 3 32/58 55.2 (41.5-68.3) 44.3 53.3 (36,1-70.2) 
PTB <28 weeks 2 3/30 10.0 (2.1-26.5) 68.1 9.7 (2.0-22.3) 
Stage IV 
PTB <34 weeks  2 3/7 42.9 (9.9-81.6) 73.8  46.5 (15.5-79.2) 
PTB <32 weeks 3 11/18 61.1 (35.7-82.7) 0 59.9 (37.9-80.0) 
PTB <28 weeks 2 0/7 0.0 (0-41.0) 0 0.0 (0-30.7) 
Stage V 
PTB <34 weeks  - - - - - 
PTB <32 weeks - - - - - 
PTB <28 weeks - - - - - 
 







Table 6. Pooled proportions for morbidity in MCDA twins affected by TTTS according to the stage of the disease. (95% confidence intervals, CI, 
between parentheses). 
 
Outcome Studies (n) Fetuses (n/N) Raw proportions (95% CI) I2 (%) Pooled Proportions (95% CI) 
Stage I 
Composite morbidity 3 44/188 23.4 (17.6-30.19) 97.7 22.9 (0.1-68.49) 
Neurological morbidity (overall) 2 2/148 1.4 (1.6-4.8) 42.8 1.5 (0.02-5.1) 
Severe neurological morbidity 2 2/84 2.4 (0.2-8.3) - - 
Respiratory morbidity 1 16/84 19.1 (11.3-29.1) - - 
Stage II 
Composite morbidity 2 39/124 31.5 (23.4-40.4) 98.9 28.8 (6.8-97.0) 
Neurological morbidity (overall) 2 6/124 4.8 (1.8-10.2) 74.2 5.2 (0.3-15.4) 
Severe neurological morbidity 1 5/54 9.3 (3.1-20.3) - - 
Respiratory morbidity 1 38/54 70.4 (56.4-82.0) - - 
Stage III 
Composite morbidity 2 48/127 37.8 (29.3-46.8) 98.5 29.3 (18.6-91.8) 
Neurological morbidity (overall) 2 8/127 6.3 (2.8-12.0) 12.3 6.7 (2.9-12.1) 
Severe neurological morbidity 1 6/71 8.5 (3.2-17.5) - - 
Respiratory morbidity 1 46/71 64.8 (52.5-75.8) - - 
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Stage IV 
Composite morbidity 2 21/64 32.8 (21.6-45.7) 93.4 24.1 (0.02-71.8) 
Neurological morbidity (overall) 2 3/64 4.7 (1.0-13.1) 0 5.9 (1.6-13.0) 
Severe neurological morbidity 1 2/42 7.1 (1.5-19.5) - - 
Respiratory morbidity 1 20/42 47.6 (32.0-63.6) - - 
Admission to NICU      
Stage V 
Composite morbidity - - - - - 
Neurological morbidity (overall) - - - - - 
Severe neurological morbidity - - - - - 
Respiratory morbidity - - - - - 
 
 
Table 7. Pooled proportions for single and double survival in MCDA twin pregnancies affected by stage I TTTS according to different management 
options (expectant, laser and amnioreduction). (95% confidence intervals, CI, between parentheses). 
Outcome Studies (n) Fetuses (n/N) Raw proportions (95% CI) I2 (%) Pooled Proportions (95% CI) 
 Stage I (expectant) 
No survivor 4 18/112 16.1 (9.8-24.2) 67 15.1 (4.9-29.6) 
One survivor 3 18/108 16.7 (10.2-25.1) 0 17.5 (11.0-25.1) 
At least one survivor 4 94/112 83.9 (75.8-90.2) 67 84.9 (70.4-95.1) 
Two survivors 3 73/108 67.6 (57.9-76.3) 29.4 67.9 (57.0-77.9) 
      
 Stage I (laser therapy) 
No survivor 10 36/285 12.6 (9.0-17.1) 0 13.2 (9.6-17.4) 








One survivor 10 46/285 16.1 (12.1-20.9) 0 16.7 (12.6-21.2) 
At least one survivor 10 249/285 87.4 (82.9-91.0) 0 86.7 (82.6-90.4) 
Two survivors 10 203/285 71.2 (65.6-76.4) 37.9 69.7 (61.6-77.1) 
 Stage I (amnioreduction) 
No survivor 3 4/60 6.7 (1.8-16.2) 0 7.8 (2.5-15.8) 
One survivor 3 7/60 11.7 (4.8-22.6) 62.1 12.9 (2.5-30.1) 
At least one survivor 3 56/60 93.3 (83.8-98.2) 0 92.2 (84.2-97.6) 
Two survivors 3 49/60 81.7 (69.6-90.5) 61.7 80.8 (62.0-94.2) 
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